🇺🇸 FDA
Patent

US 9868949

Organic compositions to treat EPAS1-related diseases

granted A61KA61K31/7105A61K31/7115

Quick answer

US patent 9868949 (Organic compositions to treat EPAS1-related diseases) held by Arrowhead Pharmaceuticals, Inc. expires Mon Jan 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Arrowhead Pharmaceuticals, Inc.
Grant date
Tue Jan 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/7105, A61K31/7115, A61K31/712, A61K31/7125